Compare Biocon with Sanofi India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs SANOFI INDIA - Comparison Results

BIOCON      Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON SANOFI INDIA BIOCON /
SANOFI INDIA
 
P/E (TTM) x 31.5 39.5 79.6% View Chart
P/BV x 3.7 8.1 46.6% View Chart
Dividend Yield % 0.3 1.1 24.2%  

Financials

 BIOCON    SANOFI INDIA
EQUITY SHARE DATA
    BIOCON
Mar-19
SANOFI INDIA
Dec-18
BIOCON /
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs7076,840 10.3%   
Low Rs5544,630 12.0%   
Sales per share (Unadj.) Rs91.91,203.1 7.6%  
Earnings per share (Unadj.) Rs16.7165.3 10.1%  
Cash flow per share (Unadj.) Rs24.2209.9 11.5%  
Dividends per share (Unadj.) Rs1.0084.00 1.2%  
Dividend yield (eoy) %0.21.5 10.8%  
Book value per share (Unadj.) Rs101.6963.6 10.5%  
Shares outstanding (eoy) m600.0023.03 2,605.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.94.8 143.9%   
Avg P/E ratio x37.734.7 108.7%  
P/CF ratio (eoy) x26.127.3 95.4%  
Price / Book Value ratio x6.26.0 104.2%  
Dividend payout %6.050.8 11.8%   
Avg Mkt Cap Rs m378,330132,078 286.4%   
No. of employees `0006.13.3 185.7%   
Total wages/salary Rs m11,6534,068 286.5%   
Avg. sales/employee Rs Th8,994.38,393.8 107.2%   
Avg. wages/employee Rs Th1,900.71,232.4 154.2%   
Avg. net profit/employee Rs Th1,635.31,153.0 141.8%   
INCOME DATA
Net Sales Rs m55,14427,708 199.0%  
Other income Rs m1,444897 161.0%   
Total revenues Rs m56,58828,605 197.8%   
Gross profit Rs m15,8836,235 254.7%  
Depreciation Rs m4,4781,027 436.0%   
Interest Rs m7097 10,128.6%   
Profit before tax Rs m12,1406,098 199.1%   
Minority Interest Rs m90-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,1232,292 92.6%   
Profit after tax Rs m10,0263,806 263.4%  
Gross profit margin %28.822.5 128.0%  
Effective tax rate %17.537.6 46.5%   
Net profit margin %18.213.7 132.4%  
BALANCE SHEET DATA
Current assets Rs m48,22815,922 302.9%   
Current liabilities Rs m30,3766,235 487.2%   
Net working cap to sales %32.435.0 92.6%  
Current ratio x1.62.6 62.2%  
Inventory Days Days6864 107.3%  
Debtors Days Days8621 409.8%  
Net fixed assets Rs m64,1307,539 850.6%   
Share capital Rs m3,000230 1,304.3%   
"Free" reserves Rs m57,98021,962 264.0%   
Net worth Rs m60,98022,192 274.8%   
Long term debt Rs m15,7660-   
Total assets Rs m121,92429,839 408.6%  
Interest coverage x18.1872.1 2.1%   
Debt to equity ratio x0.30-  
Sales to assets ratio x0.50.9 48.7%   
Return on assets %8.812.8 68.9%  
Return on equity %16.417.2 95.9%  
Return on capital %16.827.5 60.9%  
Exports to sales %28.10-   
Imports to sales %18.90-   
Exports (fob) Rs m15,506NA-   
Imports (cif) Rs m10,399NA-   
Fx inflow Rs m15,5067,587 204.4%   
Fx outflow Rs m10,3997,145 145.5%   
Net fx Rs m5,107442 1,155.4%   
CASH FLOW
From Operations Rs m11,5463,739 308.8%  
From Investments Rs m-7,138-731 976.5%  
From Financial Activity Rs m-2,417-1,972 122.6%  
Net Cashflow Rs m2,1031,036 203.0%  

Share Holding

Indian Promoters % 40.4 0.0 -  
Foreign collaborators % 20.6 60.4 34.1%  
Indian inst/Mut Fund % 8.4 14.4 58.3%  
FIIs % 10.7 14.6 73.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 10.5 189.5%  
Shareholders   109,995 15,184 724.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON With:   ALKEM LABORATORIES  FRESENIUS KABI ONCO.  TTK HEALTHCARE  TORRENT PHARMA  STRIDES PHARMA SCIENCE  

Compare BIOCON With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 257 Points Higher; Tata Steel & Hindalco Among Top Nifty Gainers(Closing)

Indian share markets witnessed positive trading activity throughout the day today and ended higher.

Related Views on News

BIOCON Announces Quarterly Results (3QFY21); Net Profit Down 19.7% (Quarterly Result Update)

Jan 25, 2021 | Updated on Jan 25, 2021

For the quarter ended December 2020, BIOCON has posted a net profit of Rs 2 bn (down 19.7% YoY). Sales on the other hand came in at Rs 19 bn (up 5.9% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

SANOFI INDIA Announces Quarterly Results (2QFY21); Net Profit Up 5.0% (Quarterly Result Update)

Oct 29, 2020 | Updated on Oct 29, 2020

For the quarter ended September 2020, SANOFI INDIA has posted a net profit of Rs 1 bn (up 5.0% YoY). Sales on the other hand came in at Rs 7 bn (down 11.9% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

BIOCON Announces Quarterly Results (2QFY21); Net Profit Down 23.9% (Quarterly Result Update)

Oct 29, 2020 | Updated on Oct 29, 2020

For the quarter ended September 2020, BIOCON has posted a net profit of Rs 2 bn (down 23.9% YoY). Sales on the other hand came in at Rs 17 bn (up 11.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

SANOFI INDIA Announces Quarterly Results (1QFY21); Net Profit Up 39.9% (Quarterly Result Update)

Aug 26, 2020 | Updated on Aug 26, 2020

For the quarter ended June 2020, SANOFI INDIA has posted a net profit of Rs 1 bn (up 39.9% YoY). Sales on the other hand came in at Rs 7 bn (down 5.0% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA Announces Quarterly Results (4QFY20); Net Profit Down 8.1% (Quarterly Result Update)

May 21, 2020 | Updated on May 21, 2020

For the quarter ended March 2020, SANOFI INDIA has posted a net profit of Rs 854 m (down 8.1% YoY). Sales on the other hand came in at Rs 8 bn (up 9.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

More Views on News

Most Popular

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

Sell in May and Go Away?(Fast Profits Daily)

Apr 28, 2021

Does the concept of selling stocks in the month of May, work in the Indian market?

This Fund Manager Has Taken the World by Storm. Will You Invest With Her?(Profit Hunter)

Apr 26, 2021

Should you invest with this Rockstar fund manager who has outperformed in a big way?

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


May 7, 2021 (Close)

TRACK BIOCON

BIOCON - FRESENIUS KABI ONCO. COMPARISON

COMPARE BIOCON WITH

MARKET STATS